{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:56:17Z","timestamp":1781632577992,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Henan Provincial Science Fund for Distinguished Young Scholars, China","award":["232300421011"],"award-info":[{"award-number":["232300421011"]}]},{"name":"Program for Science & Technology Innovation Talents in Universities of Henan Province, China","award":["24HASTIT064"],"award-info":[{"award-number":["24HASTIT064"]}]},{"name":"Young and Middle-aged Academic Leaders of Health Commission of Henan Province, China","award":["HNSWJW-2023029"],"award-info":[{"award-number":["HNSWJW-2023029"]}]},{"name":"Henan Provincial Clinical Medical Scientist Program, China","award":["HNCMS202416"],"award-info":[{"award-number":["HNCMS202416"]}]},{"name":"Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University, China","award":["QNCXTD2023014"],"award-info":[{"award-number":["QNCXTD2023014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Data on the clinical features and treatment of young children with acute hepatitis C (AHC) remain limited. This case-series report describes the clinical characteristics, histopathological findings, and treatment responses of two young children with AHC, aiming to provide insights for future research and clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>We evaluated two four-year-old children who acquired AHC through unsafe injection practices. The clinical decision-making process and management strategies were documented, and both children underwent liver biopsy. They received an eight-week course of sofosbuvir\/velpatasvir (200\/50\u00a0mg; \u00bd tablet, tablet-split, once daily). The primary efficacy endpoint was sustained virologic response (SVR12), defined as undetectable HCV RNA 12 weeks after completing treatment. Adverse events were monitored throughout the therapy period. Both children were asymptomatic at diagnosis. Baseline HCV RNA levels were 1,500 IU\/mL and 2,300 IU\/mL, with alanine aminotransferase (ALT) levels of 316 U\/L and 15 U\/L, respectively. Liver biopsy revealed mild inflammation with moderate fibrosis (G1S2) in child 1 and moderate inflammation with mild fibrosis (G2S1) in child 2. By the first week of therapy, ALT levels normalized in both cases; HCV RNA declined to 49.2 IU\/mL in child 1 and became undetectable in child 2. By week 2, HCV RNA was undetectable in child 1. At 12 weeks after treatment completion, both achieved SVR12, with no treatment-related adverse events and stable laboratory parameters throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report clearly demonstrating that AHC in young children can cause histological liver injury. An eight-week tablet-split regimen of sofosbuvir\/velpatasvir appeared safe, well tolerated, and effective in these two cases. Further studies are warranted to validate these findings in the broader pediatric population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12681-4","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:46:49Z","timestamp":1769759209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Histopathological features and eight-week split-tablet sofosbuvir\/velpatasvir treatment in young children with acute hepatitis C: a case-series study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ya-Jie","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"12681_CR1","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Panel A-IHG, Hepatitis C. Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023; online."},{"issue":"2","key":"12681_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2024.04.007","volume":"81","author":"T Reiberger","year":"2024","unstructured":"Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol. 2024;81(2):326\u201344.","journal-title":"J Hepatol"},{"issue":"1","key":"12681_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11894-024-00955-3","volume":"27","author":"J Ferreira","year":"2025","unstructured":"Ferreira J, Sheflin-Findling S. Update on pediatric hepatitis C infection. Curr Gastroenterol Rep. 2025;27(1):18.","journal-title":"Curr Gastroenterol Rep"},{"issue":"5","key":"12681_CR4","doi-asserted-by":"publisher","first-page":"e70026","DOI":"10.1111\/jvh.70026","volume":"32","author":"X Wang","year":"2025","unstructured":"Wang X, Yan X, He B, Li B, Huang L, Li J, et al. Global burden and trends of acute hepatitis C from 1990 to 2021: an analysis based on the 2021 global burden of disease study. J Viral Hepat. 2025;32(5):e70026.","journal-title":"J Viral Hepat"},{"key":"12681_CR5","doi-asserted-by":"crossref","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, Group C. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013;2013.","DOI":"10.1136\/bcr-2013-201554"},{"issue":"4","key":"12681_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12072-015-9671-8","volume":"9","author":"SS Zhu","year":"2015","unstructured":"Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, et al. Interferon-alpha plus ribavirin yields 98% sustained virologic response in children aged 1\u20135 years with iatrogenic chronic hepatitis C. Hepatol Int. 2015;9(4):578\u201385.","journal-title":"Hepatol Int"},{"issue":"9796","key":"12681_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(11)61460-8","volume":"378","author":"T Yang","year":"2011","unstructured":"Yang T, Wu MC. Discrimination against hepatitis B carriers in China. Lancet. 2011;378(9796):1059.","journal-title":"Lancet"},{"issue":"3","key":"12681_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372\u20134.","journal-title":"J Hepatol"},{"issue":"9","key":"12681_CR9","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1002\/jmv.27877","volume":"94","author":"QL Zeng","year":"2022","unstructured":"Zeng QL, Yu ZJ, Lv J, Zhang HX, Wang B, Dong XP, et al. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study. J Med Virol. 2022;94(9):4548\u201353.","journal-title":"J Med Virol"},{"issue":"23","key":"12681_CR10","first-page":"1135","volume":"33","author":"E D\u2019Amico","year":"1981","unstructured":"D\u2019Amico E, Fiozzi MC. Non-A non-B acute viral hepatitis. 2 pediatric cases. Minerva Pediatr. 1981;33(23):1135\u20138.","journal-title":"Minerva Pediatr"},{"issue":"1","key":"12681_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmv.1890350102","volume":"35","author":"SC Hsu","year":"1991","unstructured":"Hsu SC, Chang MH, Chen DS, Hsu HC, Lee CY. Non-A, non-B hepatitis in children: a clinical, histologic, and serologic study. J Med Virol. 1991;35(1):1\u20136.","journal-title":"J Med Virol"},{"issue":"3","key":"12681_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","volume":"70","author":"L Modin","year":"2019","unstructured":"Modin L, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019;70(3):371\u20138.","journal-title":"J Hepatol"},{"key":"12681_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12985-016-0482-x","volume":"13","author":"B Hajarizadeh","year":"2016","unstructured":"Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, et al. Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines\/chemokines during acute hepatitis C virus infection. Virol J. 2016;13:32.","journal-title":"Virol J"},{"issue":"2","key":"12681_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tim.2003.12.005","volume":"12","author":"JM Pawlotsky","year":"2004","unstructured":"Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12(2):96\u2013102.","journal-title":"Trends Microbiol"},{"issue":"5","key":"12681_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S2468-1253(17)30003-1","volume":"2","author":"JK Rockstroh","year":"2017","unstructured":"Rockstroh JK, Bhagani S, Hyland RH, Yun C, Dvory-Sobol H, Zheng W, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2(5):347\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"12681_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.31003","volume":"72","author":"M Martinello","year":"2020","unstructured":"Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, et al. Short-Duration Pan-Genotypic therapy with Glecaprevir\/Pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020;72(1):7\u201318.","journal-title":"Hepatology"},{"issue":"4","key":"12681_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","volume":"75","author":"GV Matthews","year":"2021","unstructured":"Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, et al. Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;75(4):829\u201339.","journal-title":"J Hepatol"},{"issue":"2","key":"12681_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66(2):371\u20138.","journal-title":"Hepatology"},{"issue":"6","key":"12681_CR19","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/hep.30123","volume":"68","author":"KF Murray","year":"2018","unstructured":"Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of Ledipasvir-Sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201311. Hepatology. 2018;68(6):2158\u201366.","journal-title":"Hepatology"},{"issue":"2","key":"12681_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.30830","volume":"71","author":"KB Schwarz","year":"2020","unstructured":"Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, et al. Ledipasvir-Sofosbuvir for 12 weeks in children 3 to <\u20096 years old with chronic hepatitis C. Hepatology. 2020;71(2):422\u201330.","journal-title":"Hepatology"},{"issue":"3","key":"12681_CR21","doi-asserted-by":"publisher","first-page":"100650","DOI":"10.1016\/j.jhepr.2022.100650","volume":"5","author":"B Maasoumy","year":"2023","unstructured":"Maasoumy B, Ingiliz P, Spinner CD, Cordes C, Stellbrink HJ, Schulze Zur Wiesch J, et al. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: the HepNet acute HCV-V study. JHEP Rep. 2023;5(3):100650.","journal-title":"JHEP Rep"},{"issue":"9","key":"12681_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/hepr.14032","volume":"54","author":"S Nakano","year":"2024","unstructured":"Nakano S, Suzuki M, Hatori R, Mizuochi T, Etani Y, Tajiri H. Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan. Hepatol Res. 2024;54(9):795\u2013806.","journal-title":"Hepatol Res"},{"key":"12681_CR23","doi-asserted-by":"publisher","first-page":"102727","DOI":"10.1016\/j.eclinm.2024.102727","volume":"74","author":"JWE Quek","year":"2024","unstructured":"Quek JWE, Loo JH, Lim EQ, Chung AH, Othman ABB, Tan JJ, et al. Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis. EClinicalMedicine. 2024;74:102727.","journal-title":"EClinicalMedicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12681-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:23:14Z","timestamp":1781630594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12681"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12681-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008. Written informed consent was obtained from the parents before the initiation of the treatment. This study was approved by the ethics committee of The First Affiliated Hospital of Zhengzhou University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all the parents of the children.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}